Eli Lilly spent fourteen years and four separate Phase 3 populations trying to make solanezumab work, and the compound never […]

Teva’s ProAir HFA inhaler illustrates the gap better than any definition can. The active ingredient, albuterol sulfate, went off patent

In 2007, a federal judge in the Southern District of New York ordered two generic drug companies to pay Takeda

AbbVie’s core patent on Humira, the one covering the adalimumab molecule itself, expired in January 2016. U.S. biosimilars did not

Teva Pharmaceutical Industries paid Pfizer and Takeda $1.6 billion in 2013. Sun Pharma paid another $550 million. The combined $2.15

Every generic and biosimilar developer knows the standard playbook. Wait for the composition-of-matter patent to run out, clear the Orange

Every generics attorney has heard some version of the same sentence from a nervous client: “They have over a hundred

Settling a Paragraph IV patent case feels like the safe choice. It ends the uncertainty, it gets a launch date

A generic company spends four years and fifteen million dollars fighting for the right to be first. It wins. It